A new mucoadhesive dosage form for the management of oral lichen planus: formulation study and clinical study

Eur J Pharm Biopharm. 2010 Nov;76(3):437-42. doi: 10.1016/j.ejpb.2010.07.014. Epub 2010 Aug 11.

Abstract

The work aimed at studying a new mucoadhesive prolonged release tablet containing 24 μg clobetasol-17 propionate (CP) suitable for the management of oral lichen planus. Low swellable dosage forms were designed by combining a mucoadhesive polymer, i.e. poly(sodium methacrylate, methylmethacrylate), with hydroxypropylmethylcellulose and MgCl₂. This formulation was selected to modify the tablet erosion rate in order to obtain a release of CP over a 6-h period. A double-blind, controlled study was performed using three groups of patient (n=16) who received three applications-a-day over 4 weeks of the developed CP tablets (group CP-T), placebo tablets (group CP-P) or commercial CP ointment for cutaneous application (123 μg/application) extemporary mixed with Orabase™ (group CP-O). At the end of the study, pain and ulceration resolved in 13/16 and 11/16 patients of group CP-T and group CP-O, respectively. In the group CP-O, a transient acute hyperaemic candidosis (n=2) and taste alteration (n=4) were also observed. No changes in clinical signs of patients in the group CP-P were evident. The application of mucoadhesive tablet containing 24 μg CP 3 times a day appeared to be effective, avoiding the side effects of the generally used treatment.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Adult
  • Aged
  • Clobetasol / administration & dosage*
  • Clobetasol / analysis
  • Clobetasol / metabolism
  • Clobetasol / therapeutic use
  • Delayed-Action Preparations
  • Dosage Forms
  • Double-Blind Method
  • Drug Delivery Systems*
  • Female
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / analysis
  • Glucocorticoids / metabolism
  • Glucocorticoids / therapeutic use
  • Humans
  • Lichen Planus, Oral / drug therapy*
  • Male
  • Middle Aged

Substances

  • Delayed-Action Preparations
  • Dosage Forms
  • Glucocorticoids
  • Clobetasol